相关实验视频
Updated: Jun 28, 2025
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
23.2K
通过人工智能和对低过敏性虫过敏原Der f 36疫苗的免疫化构建
Qiao-Zhi Qin1,2, Jian Tang3, Cai-Yun Wang1
1Department of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China.
Frontiers in immunology
|April 11, 2024
概括
人工智能设计了一种低过敏性室内灰尘虫 (HDM) 疫苗,针对特定的B细胞表位. 这种新型疫苗显示过敏性降低,并诱导阻断IgG抗体,为HDM过敏提供了有前途的新免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 生物工程是生物工程.
- 计算生物学 计算生物学
背景情况:
- 家庭灰尘 (HDM) 过敏是一种普遍的全球健康问题.
- 过敏原特异性免疫疗法 (AIT) 是对HDM过敏的一种成熟治疗方法.
- 新型低过敏疫苗的开发对于推进AIT至关重要.
研究的目的:
- 使用人工智能 (AI) 开发一种基于B细胞表位的低过敏性B细胞过敏疫苗.
- 评估人工智能设计的疫苗的降低过敏性和免疫性.
- 评估这种疫苗作为HDM过敏患者的新型免疫疗法的潜力.
主要方法:
- 使用AlphaFold2.2构建了Derf 36的3D蛋白质结构.
- 利用人工智能工具来预测和实验验证B细胞表位.
- 合成,表达和净化的低过敏性Derf 36;通过ELISA,免疫血栓和基激活测试评估过敏性.
- 在PBMC和子免疫中通过细胞因子表达评估T细胞反应和免疫性.
- 研究了阻断IgG抗体对IgE结合和基细胞激活的抑制作用.
主要成果:
- 鉴定并选择了五种非过敏B细胞表位.
- 低过敏性Derf 36的IgE结合活性显著降低 (20%的抑制率与本地Derf 36的98%相比).
- 表现出低基因细胞刺激比率,诱导了没有Th2细胞因子的IFN-γ,并产生了疫苗特定的IgG抗体,能够阻止IgE结合和基因细胞激活.
结论:
- 这项研究是第一个应用人工智能策略来开发基于B细胞表位的低过敏Derf 36疫苗的研究.
- 人工智能设计的疫苗表现出降低的过敏性和强大的免疫性,诱导阻断IgG抗体.
- 这种低过敏的Derf 36疫苗有望成为未来的免疫疗法,用于家庭灰尘虫过敏.
相关概念视频
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
01:51Vaccinations
44.4K
Overview
44.4K
01:26Antigens Involved in Adaptive Immunity
487
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
487
01:10Antibody Structure
60.1K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.1K